Quantcast

Latest epilepsy Stories

2014-07-18 23:01:32

Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/epilepsy-therapeutics-market.html. (PRWEB) July 18, 2014 Epilepsy is a group of long-term neurological disorders that is characterized by recurring seizures. These seizures are episodes that occur when group of nerve cells or neurons in brain sends...

2014-07-17 16:20:33

Attribute to Susan Axelrod, Founding Chair, Citizens United for Research in Epilepsy (CURE) CHICAGO, July 17, 2014 /PRNewswire-USNewswire/ -- "CURE applauds the announcement today from the U.S. Department of Defense - allocating $7.5 million dedicated to epilepsy research - and thanks Senator Dick Durbin (D-IL) for his leadership on this issue. The incidence of epilepsy increased by an alarming 52 percent from 2006 to 2010, with approximately 8 percent of those afflicted having been...

2014-07-16 20:23:07

LONDON, July 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability https://www.reportbuyer.com/product/2052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html Epilepsy Therapeutics in Asia Pacific...

2014-07-15 16:27:31

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patternshttps://www.reportbuyer.com/product/2052297/Epilepsy-Therapeutics-in-Major-Developed-Markets-to-2019---New-AEDs-with-Novel-Mechanisms-of-Action-Signal-a-Shift-in-Treatment-Patterns.htmlEpilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with...

2014-07-15 08:28:37

WAYNE, Pa. and PORTO, Portugal, July 15, 2014 /PRNewswire/ -- BIAL, a research based international pharmaceutical company, and moksha8, a leading specialty pharmaceutical company in Latin America, announced today an exclusive license for the commercialization of eslicarbazepine acetate (Zebinix® / (Exalief®) in Brazil and Mexico for the treatment of epilepsy. Epilepsy is one of the most common neurological diseases, affecting 70 million worldwide and up to 5 million people in Latin America...

2014-07-14 08:27:51

Authorized Generic Topiramate Extended-Release Capsules Available Nationwide MAPLE GROVE, Minn., July 14, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced the launch of Topiramate Extended-Release Capsules, the authorized generic of the recently Food and Drug Administration (FDA) approved Qudexy(TM) XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK)...

2014-07-11 08:24:53

MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that Health Canada approved APTIOM(TM) (eslicarbazepine acetate) for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy. APTIOM(TM) is not indicated for use in patients under 18 years of age. Epilepsy is one of the most common neurological disorders and...

2014-07-11 08:24:35

Agreement with Biotie ends option for purchase and allows Neurelis to advance development of NRL-1 in preparation for NDA filing SAN DIEGO, July 11, 2014 /PRNewswire/ -- Neurelis, Inc. ("Neurelis") today announced an agreement with Biotie Therapies Corp. ("Biotie") to end the option held by Biotie to purchase Neurelis, clearing the way for Neurelis to commence further development of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy patients who experience acute repetitive...

2014-07-09 23:10:43

Expanding market reach to Europe for its innovative software solution for automated brain atrophy measurements. San Diego, CA (PRWEB) July 09, 2014 CorTechs Labs, Inc. is pleased to announce that it has received CE Marking allowing the distribution in the European Economic Area (EEA) of their software product NeuroQuant, the leading volumetric brain imaging device. Already FDA Cleared and used by many reputable clinics and hospitals, NeuroQuant provides cutting-edge data analysis and...

2014-07-09 08:27:34

LOS ANGELES, July 9, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles (UCLA) focused on the treatment of...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related